Chair & Presenter, Mark A. Socinski, MD, and Jorge J. Nieva, MD, discuss Lung Cancer in this CME activity titled “Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC.” For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JBW865. CME credit will be available until May 19, 2023.YouTube
- How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC ( Download)
- How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC ( Download)
- NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment ( Download)
- Choosing immunotherapy as front line therapy for non-actionable NSCLC ( Download)
- Immunotherapy as First-Line Treatment ( Download)
- SCLC Therapy: First-line Options Prior to Immunotherapy ( Download)
- First-Line Therapy in PD-L1–Advanced NSCLC ( Download)
- How To choose first line therapy in melanoma ( Download)
- Immunotherapy/Checkpoint Inhibitor, Targeted Immunotherapy Drugs 5/2/18 ( Download)
- Using First-Line Immunotherapy in Stage 4 NSCLC ( Download)
- Choosing Therapy for Newly Diagnosed NonDriver NSCLC ( Download)
- ASCO: Combination Immunotherapy for First-Line Treatment of Advanced Lung Cancer ( Download)
- Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic Landscape ( Download)
- Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC ( Download)
- Comparative Efficacy of Chemoimmunotherapy v Immunotherapy for 1st-Line Treatment of Advanced NSCLC ( Download)
